ATE419249T1 - Inhibitoren von mitotischem kinesin - Google Patents

Inhibitoren von mitotischem kinesin

Info

Publication number
ATE419249T1
ATE419249T1 AT05732607T AT05732607T ATE419249T1 AT E419249 T1 ATE419249 T1 AT E419249T1 AT 05732607 T AT05732607 T AT 05732607T AT 05732607 T AT05732607 T AT 05732607T AT E419249 T1 ATE419249 T1 AT E419249T1
Authority
AT
Austria
Prior art keywords
compounds
inhibitors
mitotic kinesin
treating
ksp
Prior art date
Application number
AT05732607T
Other languages
English (en)
Inventor
Weibo Wang
Ryan Constantine
Liana Lagniton
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE419249T1 publication Critical patent/ATE419249T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT05732607T 2004-04-06 2005-04-06 Inhibitoren von mitotischem kinesin ATE419249T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56023504P 2004-04-06 2004-04-06

Publications (1)

Publication Number Publication Date
ATE419249T1 true ATE419249T1 (de) 2009-01-15

Family

ID=34964986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05732607T ATE419249T1 (de) 2004-04-06 2005-04-06 Inhibitoren von mitotischem kinesin

Country Status (15)

Country Link
US (3) US7504405B2 (de)
EP (1) EP1732926B1 (de)
JP (1) JP4895220B2 (de)
KR (1) KR20060135035A (de)
CN (1) CN1984912A (de)
AT (1) ATE419249T1 (de)
AU (1) AU2005233576A1 (de)
BR (1) BRPI0509653A (de)
CA (1) CA2561904A1 (de)
DE (1) DE602005012069D1 (de)
ES (1) ES2318478T3 (de)
PL (1) PL1732926T3 (de)
PT (1) PT1732926E (de)
RU (1) RU2006138864A (de)
WO (1) WO2005100357A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006018628A1 (en) * 2003-03-07 2006-02-23 Astrazeneca Ab Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer
US20060270689A1 (en) * 2003-03-07 2006-11-30 Astrazeneca Ab Novel Fused Heterocycles and Uses Thereof
JP4895220B2 (ja) * 2004-04-06 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キネシン有糸分裂インヒビター
MXPA06014909A (es) * 2004-06-18 2007-02-28 Chiron Corp Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer.
MX2007000809A (es) * 2004-07-22 2007-03-21 Astrazeneca Ab Pirimidonas fusionadas utiles en el tratamiento y la prevencion de cancer.
BRPI0514390A (pt) 2004-08-18 2008-06-10 Astrazeneca Ab enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
EP2091926B1 (de) * 2006-11-13 2015-10-21 Novartis AG Substituierte pyrazol- und triazolverbindungen als ksp-inhibitoren
CN101622247A (zh) * 2007-01-05 2010-01-06 诺瓦提斯公司 作为驱动蛋白纺锤体蛋白抑制剂的咪唑衍生物
WO2010042392A2 (en) * 2008-10-06 2010-04-15 Merck & Co., Inc. Hiv integrase inhibitors
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2157285B (en) 1984-04-11 1987-10-28 Erba Farmitalia 1h, 7h-pyrazolo1, 5-a pyrimidine-7-one derivatives and process for their preparation
CA2468266A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Substituted bicyclic pyrimidinones as a mitotic kinesin ksp inhibitors
MXPA04011074A (es) 2002-05-09 2005-06-08 Cytokinetics Inc Compuestos de pirimidinona, composiciones y metodos.
EP1513820A4 (de) 2002-05-23 2006-09-13 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
WO2004064741A2 (en) 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
ES2339862T3 (es) * 2003-06-20 2010-05-26 Novartis Vaccines And Diagnostics, Inc. Compuestos de piridino 1,2-a-pirimidin-4-ona como agentes anticancerosos.
JP4895220B2 (ja) * 2004-04-06 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キネシン有糸分裂インヒビター

Also Published As

Publication number Publication date
RU2006138864A (ru) 2008-05-20
PT1732926E (pt) 2009-04-03
AU2005233576A1 (en) 2005-10-27
BRPI0509653A (pt) 2007-10-09
EP1732926A1 (de) 2006-12-20
US20090171082A1 (en) 2009-07-02
US20050228002A1 (en) 2005-10-13
US20080249112A1 (en) 2008-10-09
US7504405B2 (en) 2009-03-17
JP2007532554A (ja) 2007-11-15
KR20060135035A (ko) 2006-12-28
DE602005012069D1 (de) 2009-02-12
CA2561904A1 (en) 2005-10-27
EP1732926B1 (de) 2008-12-31
PL1732926T3 (pl) 2009-06-30
WO2005100357A1 (en) 2005-10-27
JP4895220B2 (ja) 2012-03-14
CN1984912A (zh) 2007-06-20
ES2318478T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
ATE446094T1 (de) Mitotische kinesin-hemmer
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
ATE448207T1 (de) Mitotische kinesin-hemmer
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
WO2005017190A3 (en) Mitotic kinesin inhibitors
TW200510380A (en) Mitotic kinesin inhibitors
EA200870373A1 (ru) Пиридил- и пиримидинилзамещённые производные пиррола, тиофена и фурана в качестве ингибиторов киназ
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2006068933A3 (en) Mitotic kinesin inhibitors
WO2005065183A3 (en) Mitotic kinesin inhibitors
WO2006007496A3 (en) Mitotic kinesin inhibitors
NO20070589L (no) Mitotiske kinesin-inhibitorer.
WO2006007501A3 (en) Mitotic kinesin inhibitors
WO2006023440A3 (en) Mitotic kinesin inhibitors
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
WO2005060654A3 (en) Mitotic kinesin inhibitors
UA86051C2 (en) Substituted quinoline compounds
WO2004087050A3 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1732926

Country of ref document: EP